Recruiting

Testing a safer way to measure lung safety before liver cancer treatment

Plain-English translation of NCT07476651 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.

What is this trial?

This trial is testing a new, more accurate way to predict whether radioactive beads (SIR-Spheres) will safely treat your liver cancer without damaging your lungs. Currently, doctors use an older test particle to estimate this risk before treatment, but the new method uses a tiny dose of the actual treatment beads to get a more precise answer on the day of your procedure.

The current safety test sometimes overestimates lung risk because it uses particles that are slightly different from the actual treatment beads. Additionally, the standard test material has had worldwide supply problems. This new approach aims to be more accurate, reliable, and available.

Do you qualify?

You likely qualify if…

you are 19 years or older
you have been diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or liver metastases
you have at least 30% of healthy liver remaining outside the tumor area
you have a Child-Pugh class A liver function rating
your most recent lung safety scan (MAA scan) showed 20% or less radiation reaching your lungs
your blood work shows your liver, kidneys, and blood cells are functioning well

You likely don't qualify if…

you have had biliary stent placement or biliary-enteric surgery
your chest imaging shows severe emphysema or lung scarring that could make even mild radiation damage life-threatening
you have a severe allergy to iodinated contrast dye used in imaging
you cannot safely undergo angiography or catheter procedures
your lung safety scan (MAA scan) showed more than 20% radiation reaching your lungs

What participation looks like

On the day of your treatment, you will receive a small test injection of the actual radioactive beads into the artery feeding your liver tumor. A PET/CT scan will then measure how much of this tiny dose reaches your lungs versus stays in the liver. This information helps your doctor confirm the treatment is safe for you before proceeding with the full therapeutic dose, which typically happens the same day or within one to two weeks.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Trial locations(1 site)

South Korea

Seoul National University Hospital, Seoul

View full record on ClinicalTrials.gov